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Background: Often affecting knee joints, osteoarthritis (OA) is the most common type of arthritis and by 2020 is
predicted to become the fourth leading cause of disability globally. Without cure, medication management is
symptomatic, mostly with simple analgesics such as acetaminophen and non-steroidal anti-inflammatory drugs
(NSAIDs), and glucosamine sulfate. Adherence to arthritis medications is generally low. Intentional non-adherence,
that is deliberate decision-making about the use of analgesics, occurs in OA patients. To date, a limited number of
studies have explored medication-taking decisions in people with OA nor the extent to which individuals’ trade off
one treatment factor for another in their decision-making using quantitative techniques. This study aimed to
estimate the relative influence of medication-related factors and respondent characteristics on decisions to
continue medications among people with symptomatic OA.
Methods: A discrete choice experiment (DCE) was conducted among participants attending end-of-study visits in
the Long-term Evaluation of Glucosamine Sulfate (LEGS) study (ClinicalTrials.gov ID: NCT00513422). The paper-based
survey was used to estimate the relative importance of seven medication specific factors (pain efficacy, mode of
action, dose frequency, treatment schedule, side effects, prescription, and out-of-pocket costs) and respondent
characteristics on decisions to continue medications.
Results: 188 (response rate 37%) completed surveys were returned. Four of the seven medication factors (side
effects, out-of-pocket costs, mode of action, treatment schedule) had a significant effect on the choice to continue
medication; patient characteristics did not. Assuming equivalent pain efficacy and disease-modifying properties for
glucosamine, the positive relative likelihood of continuing with sustained-release acetaminophen was equivalent to
glucosamine. By contrast, the negative relative likelihood of NSAID continuation was mostly driven by the side
effect profile. The predicted probability of continuing with glucosamine decreased with increasing out-of-pocket
costs.
Conclusions: This study has characterised the complexity of medication-taking decisions that potentially underpin
intentional non-adherent behaviour for people with symptomatic OA. In particular, medication risks and cost were
important and ought to be borne into considerations in interpreting clinical trial evidence for practice. Ultimately
addressing these factors may be the way forward to realising the full potential of health and economic benefits
from the efficacious and safe use of OA medications.
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Osteoarthritis (OA) is a musculoskeletal disease that
causes chronic joint pain and reduced physical function-
ing. Often affecting knee joints, OA is the most common
type of arthritis. By 2020, OA is predicted to become the
fourth leading cause of disability globally [1].
Currently there is no known cure for OA, nor are there
effective interventions to slow disease progression [2-4].
Medication management is symptomatic, mostly with sim-
ple analgesics such as acetaminophen and non-steroidal
anti-inflammatory drugs (NSAIDs) [5,6]. Increasingly, glu-
cosamine sulfate (GS) [7], is being used as a potential anal-
gesic and disease-modifying agent [3,8-11]. In Australia, GS
is considered a dietary supplement and is purchased with-
out prescription. Unlike other OA medications, the cost of
GS is not subsidised by the Australian government [12].
As occurs with most chronic conditions, adherence to
arthritis medications is low [4,13-16]. Factors implicated
in adherence to OA and other anti-rheumatic medications
include dosing frequency [16], pain and self-efficacy levels
[13], and physician trust [4,17,18]. Intentional non-
adherence [19], that is deliberate decision-making about
the use of OA medications, is reported in the literature. In
particular, intentional under-dosing and rationing of anal-
gesics occurs [20-22]. Such decisions appear to be driven
by factors including the fear of addiction [20], previous
medication effectiveness, and the burden and illness
stigma represented by increased pill loads [21]. For
NSAIDs specifically, a high level of trust in the prescribing
physician influences decisions [22].
Primarily, qualitative methods have been used to
investigate medication decisions in OA. Although a lim-
ited number of studies have used quantitative tech-
niques, the extent to which individuals’ trade off one
treatment factor for another in decision-making about
medication adherence has not been extensively studied
[23-28]. Physicians and policy makers could use such in-
formation to tailor adherence support to match the pref-
erences of OA patients.
Discrete choice experiment (DCE) is a survey method-
ology that can be used to elicit preferences to quantita-
tively determine the relative influence of factors on
decision-making with regard to medication adherence
[29,30]. Developed initially in marketing research, DCEs
are used increasingly in health economics and are con-
sidered state-of-the-art in this field to elicit preferences
for health services [31-35]. To date, three DCE studies
have explored patient preferences for treatment factors
associated with knee and/or hip osteoarthritis [23,24,28].
In these studies, both efficacy and the gastrointestinal
side effects of treatment significantly impacted patient
choice. However, other factors potentially relevant to
OA medication adherence were not consistently in-
cluded. In particular, neither the cardiovascular, hepaticor renal side effects nor the chronic or intermittent
treatment scheduling of OA therapy were incorporated.
Additionally, preferences about acetaminophen were
omitted from one study [24].
In Australia, the LEGS (Long-term Evaluation of Glu-
cosamine Sulfate) study was a two-year, double-blind,
placebo-controlled randomised clinical trial aiming to
evaluate whether the dietary supplements, GS and/or
chondroitin can limit or reduce structural disease pro-
gression (cartilage loss), whilst providing pain relief, in
people with osteoarthritis of the knee (ClinicalTrials.gov
Identifier NCT00513422). Throughout the LEGS study,
as is typically the case in clinical trials, a number of
trial-related factors could potentially affect treatment de-
cisions and adherence outside of the trial setting. Firstly,
as a part of the study protocol, participants were regu-
larly encouraged to persist with the study treatments,
even in the absence of knee pain. Furthermore, study
treatments were mailed to participants and provided free
of charge. The use of DCEs potentially helps understand
the effects of such factors, including out-of-pocket costs,
beyond the clinical trial setting.
The Medication Decisions in Osteoarthritis Study
(MEDOS) aimed to estimate the relative influence of dif-
ferent medication-related factors and respondent charac-
teristics on decisions to continue medications among
people with symptomatic OA.
Methods
A paper-based survey was given to all LEGS participants
attending their end-of-study visit by a member of the
LEGS research team; surveys were mailed to participants
who had already completed end-of-study visits at MEDOS
commencement. The survey was self-administered and
completed either during the end-of-study visit or at a later
date and returned via mail.
Survey instrument
The survey used a DCE approach and comprised 16
hypothetical choice tasks Additional questions about self-
reported adherence to study treatment and other pre-
scribed medications during the LEGS study [36], and an
eight-item scale from the primary care assessment survey
(PCAS) [37] were also included. The PCAS has been used
in other adherence-related research [36], and assesses the
level of trust held by a patient for his/her provider.
Instrument development
In a DCE, respondents are offered a series of hypothet-
ical pairwise alternatives (choice set), and asked to nom-
inate the preferred alternative. Each alternative is
described by a set of factors with pre-specified levels.
The levels assigned to each alternative are varied succes-
sively across each choice set [32,38,39]. For this study,
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with respect to the currently available OA treatments
in Australia [3,12]. Further factor refinement occurred
through survey piloting among healthcare professionals
and a general population experienced with analgesic use.
Seven factors considered most important through survey
pre-testing and used in the final survey are summarised
in Table 1, which also includes description of the levels
of each factor. Extensive descriptions of the factors were
included in the survey introduction. Participants were
advised to contact the research team should assistance
be required.
The final survey included 16 choice sets. In each, re-
spondents were presented with hypothetical medication
alternatives, ‘Medication A’ and ‘Medication B’. To elim-
inate product recognition bias, brand names were not
used. Respondents were asked to imagine their current
pain score (as measured throughout the LEGS study)
was 9 out of 10 and they were currently taking both tab-
lets, of which their doctor was aware. Given a choice be-
tween the two medication options, respondents were
asked to indicate which medication they would prefer to
continue taking.
On the basis of the factors and levels listed in Table 1,
an orthogonal design was generated using the choice ex-
periment design software Ngene Version 1.0 [40]. Two
survey versions were created by randomly ordering the
choice sets using a random number generator [41]. The
survey was pilot tested (n = 5) to check for any problems
with interpretation and face validity; only minor changes
to the layout were made.
Participants
All LEGS participants completing their end-of-study visit
were eligible to participate in MEDOS. The eligibilityTable 1 Description of factors and levels used in the discrete
Factor Description Leve
Pain Efficacy What the pain can be reduced to (from 9/10) 1, 3,
Mode of action How the medication works Quic
Slow
Dose frequency How often taken per day 1, 3
Treatment Schedule How regularly taken Whe
Daily
Cost Cost to YOU every month $AU
Prescription Prescription/purchase restrictions Yes:
No:
Side effects Possible side effects of the medication No s
Drow
Hea
Highcriteria for participation in the LEGS study can be found
in Additional file 1 [42].
The University of Sydney Human Research Ethics
Committee (HREC 8821, amendment 4th May 2010)
and the Royal Australian College of General Practi-
tioners (NREEC 06/006, amendment 18th June 2010)
approved this study.
Analysis
The background characteristics of MEDOS participants
were summarised and compared with all LEGS partici-
pants attending their final follow-up visit. Additionally,
self-reported adherence to study treatment, cost-related
non-adherence in the past 12 months, and the trans-
formed PCAS Physician Trust domain (maximum score
100) were summarised for MEDOS participants.
For the choice data, a panel mixed multinomial (ran-
dom parameters) logit (MMNL) model was used [32,38]
to investigate changes in utility (U) (i.e. preference to
continue taking a medication) when the level of a factor
was changed using NLOGIT Version 4.0. A higher or
more positive utility indicates increased preference to
continue a medication. Additional file 2 details the
model form and analysis plan.
The effect on the final model of respondent character-
istics was investigated by forward stepwise addition
followed by backwards elimination of significant covari-
ates. A differential out-of-pocket cost factor was investi-
gated based on work status (employed, unemployed,
retired/semi-retired), as well as healthcare concession
card or private health insurance through the incorpor-
ation of cost-factor interaction terms.
From the final model, the odds ratio (OR) of each fac-
tor was calculated (i.e. OR = exp(β)), representing the in-
fluence of the factor on the choice to continue achoice experiment
ls
4, 7




S 5, 20, 35 50
(pharmacy with prescription)




blood pressure, heart/kidney/liver problems
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medication profiles for GS, sustained-release acetamino-
phen, and selective and non-selective NSAIDs by input-
ting the factor levels outlined in Table 2. This represents
the relative likelihood of continuing each medication
profile: an OR greater than 1 represents an increased
preference to continue taking medication.
The willingness to accept (WTA) for each factor was
estimated by taking the marginal rate of substitution be-
tween the factor and cost (βfactor/βcost) [43]. This de-
scribes the amount of money respondents believe
compensates for a given change in the factor.
The relative importance of factors and their levels was
also investigated [34]. This reflects the extent to which
the difference between the best and worst levels of each
characteristic drives the decision to continue taking a
medication.
Finally, the predicted probability of continuing GS was
calculated using the factor levels outlined in Table 2
[44]. As the cost of GS is variable within Australia, a
cost sensitivity analysis was conducted for the predicted
probability.
Results
503 LEGS participants attended the end-of-study visits;
59 participants had already attended the end-of-study
visit at MEDOS commencement and were mailed a sur-
vey. The remaining participants were given a survey at
the end-of-study visit.
188 (response rate 37%) completed surveys were
returned. Table 3 displays the background characteristics
for all LEGS participants attending their end-of-study
visit, and the subset of these participants completing the
MEDOS study. With the exception of a lower proportion
of people taking “when required” medications in the
MEDOS group, there does not appear to be evidence for
difference.
For the MEDOS participants, self-reported adherence
to the study treatment throughout the LEGS study was




Pain Efficacy 1 1 1
Mode of Action Slow OA Quick Quick
Dose Frequency Three Three Once
Treatment Schedule Daily Daily Daily
Cost ($AU)a $20 $12.00 $34.20
Prescription No No Yes
Side effects Nil Nil High b
liver pr
a The out-of-pocket costs represent those that would have been incurred at the timlowest adherence rate reported was 75%. For other med-
ications, 24% of participants reported intentionally stop-
ping or altering the dose during the previous 12 months.
In general, MEDOS study participants had a high level
of trust in their primary care physician (median PCAS
score 75 out of 100).
DCE results
Table 4 shows the results of the DCE. An estimated OR
of 0.90 implies that changing the treatment schedule
from “when required” to “daily treatment” decreases the
likelihood of continuing a medication by 10%, if all other
factors are held equal. Likewise, an OR of 0.09 implies
that changing from a medication with no side effects to
one that may cause high blood pressure, heart, kidney,
or liver side effects decreases the likelihood of continu-
ing a medication by 91%.
Four of the seven factors had a significant effect on
the choice to continue a medication: out-of-pocket costs,
side effects, mode of action, and treatment schedule.
Pain efficacy, dose frequency, and whether one’s access
to the medication was restricted through prescription
and place of purchase did not significantly influence
medication choice. The signs of all significant parameters
were in the expected direction except for the side effect of
drowsiness and constipation, which was positive. A signifi-
cant constant term (α) indicates that other unmeasured
factors considered by respondents, but not included in this
experiment, influenced patient decision-making.
Inputting background characteristics into the model
did not improve the model fit, nor were the associated
β-parameters significant. The relative influence of cost
on medication choice was not influenced by health care
concession card status, private health insurance status,
or work status.
The WTA for each factor is displayed in Table 4. Re-
spondents were willing to accept high blood pressure,
heart/kidney/liver problems as a side effect if compen-
sated with up to $92 per month. By contrast, respon-
dents were willing to accept up to $14 per month for adicted probabilities










e of the survey for non-healthcare concession cardholders.
Table 3 Background characteristics
Responders (n = 188) Missing (n) All (n = 503) Missing (n)
Age (mean, SD), years 62, 8.5 15 62, 8 1
Gender (n, %), male 84 (48%) 15 230 (46%) 1
Private Health Insurance (n, %) 108 (62%) 13 308 (61%) 0
Health Care Concession (n, %) 18 (10%) 13 56 (11%) 0
Co-morbidity with treatment (n,%)
Hypertension or Heart Disease 90 (52%) 15 213 (45%) 1
Ulcer or Stomach Disease 13 (7.5%) 15 46 (9%) 1
Kidney or Liver Disease 0 (0%) 15 4 (1%) 1
Symptom duration (≤5 years) (n, %) 92 (52%) 13 281 (56%) 0
WOMAC Pain (mean, sd) 4.1 (3.6) 0 4.2 (3.5) 0
WOMAC Physical (mean, sd) 15.9 (14.0) 0 17.0 (13.3) 0
Global assessment (mean (SD)) 1.6 (1.0) 18 1.8 (1.1) 48
SF12 MCS (mean, SD) 52.7 (10.3) 13 53.5 (9.4) 0
SF12 PCS (mean, SD) 46.3 (9.4) 13 44.4 (9.5) 0
Glucosamine/chondroitin prior (n, %) 61 (35%) 13 154 (31%) 0
Current < daily/when required medication use 5 (3%) 13 38 (8%)* 0
Adherence (study treatment) < 100%a 86(53%) 3 N/Ab N/Ab
Cost-related non-adherencea 19 (10%) 4 N/Ab N/Ab
Physician Trusta (median, range) 75 (28–100) 0 N/Ab N/Ab
* Sig P < 0.05 aMeasured in the MEDOS study only bN/A not applicable.
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parison to one that would slow OA.
The relative importance of the statistically significant
factors is displayed in Table 4. The side effect of high
blood pressure, heart/liver/kidney problems was most
important, followed by out-of-pocket costs. Respondents
were least concerned about the side effect of drowsiness
and constipation.Table 4 Discrete choice experiment results
Factor ORa (95% CI)
Pain Efficacyb (decreasing) 1.00 (0.97-1.04
Mode of actionc (Slow OAa) 1.17 (1.09-1.25
Dose frequencyb (once/day) 1.02 (0.96-1.08
Treatment Schedulec (daily) 0.90 (0.89-0.9)*
Costb (increasing) 0.97 (0.97-0.98
Prescriptionb (Yes) 1.03 (0.97-1.09
Side effects
Drowsy/constipatedc 1.55 (1.48-1.62
Heartburn/reflux, stomach ulcersc 0.76 (0.75-0.78
High blood pressure, heart/kidney/liver problemsc 0.09 (0.08-0.11
Constantb (α) N/Aa
Model Fit Statistics Log Likelihood −1271 M
*P < 0.001.
a: OR Odds Ratio, RI Relative Importance, WTA Willingness to Accept, OA Osteoarthr
b: Non-random parameter c: Random parameter.Figure 1 [45] compares the relative likelihood of continu-
ing GS, sustained-release acetaminophen, and selective and
non-selective NSAIDs. In this figure, an odds ratio of 1
equates to an average utility (U) of zero, implying that there
is no preference (either positive or negative) to continue
taking that medication. Assuming equivalent pain efficacy,
GS as a disease-modifying agent, and no side effects with
sustained-release acetaminophen, the relative likelihood ofRIa WTAa (95%CI) ($AUD)
) N/Aa 0.08 (0.04-0.11)




) N/A a 1.00 (0.83-1.16)
)* 6 18.06 (17.90-18.23)
)* 3 10.67 (10.55-10.78)
)* 1 90.50 (89.38-91.62)
N/Aa
cFaddens ρ2 adjusted 0.37 AICa 0.869
itis, N/A not applicable, AIC Akaike’s Information Criterion.
Figure 1 Relative likelihood of continuing a medication.
Laba et al. BMC Musculoskeletal Disorders 2013, 14:160 Page 6 of 9
http://www.biomedcentral.com/1471-2474/14/160continuing with sustained-release acetaminophen taken
regularly is positive and approximately equivalent to GS. By
contrast, the relative likelihood of continuing a selective or
a non-selective NSAID, taken regularly, is negative. The
cost sensitivity analysis for GS (Table 5) reveals that the
predicted probability of continued use of GS when provided
without charge is 91.6%, however when the cost rises to
$50 per month, the predicted uptake drops to 75%.
Discussion
Using DCE, this study has assessed the factors that influ-
ence the decision to continue with a medication among
a group of people with symptomatic OA. To the best of
our knowledge, this is one of few DCEs assessing medi-
cation preferences nested within a clinical trial [46], andTable 5 Cost sensitivity analyses for glucosamine sulfate









50 74.6the first in an OA clinical-trial population. Such deci-
sions underscore the concept of intentional medication
non-adherence, which may influence the translation of
clinical-trial results into practice.
This study has found that treatment factors, as opposed
to respondent characteristics including self-reported pain
levels and physical functioning, were driving adherence
decisions. Preferences to continue with OA treatments
were influenced by, in order of importance: the possibility
of high blood pressure, heart/liver/kidney problems as side
effects, out-of-pocket costs, the possibility of heartburn/
reflux, or stomach ulcers as side effects, treatment sched-
ule (i.e.: daily versus when required), mode of action
(slowing OA versus symptomatic pain relief) and the pos-
sibility of drowsiness or constipation as a side effect.
Perhaps surprisingly, treatment efficacy did not signifi-
cantly influence patient choices in this study. However
in contrast to previous DCE studies conducted among
OA patients in observational settings [23,24,28], this
study included additional factors related to treatment
schedule as well as cardiovascular, liver and renal side ef-
fects. When treatment schedule and cardiovascular, liver,
and renal side effects were taken into account, as in the
present study, their influence over patients’ treatment
preferences then seem to dominate over considerations
of treatment efficacy.
Assuming equal efficacy and GS as a disease-modifying
agent, this study has found that the relative likelihood of
continuing sustained-release acetaminophen and GS are
positive and in contrast to NSAIDs. This disparity in pre-
dicted adherence was primarily driven by negative prefer-
ences expressed for cardiovascular, liver and renal side
effects. This result may reflect an increased awareness of,
or general aversion to, NSAID-related side effects through
the recent and widely publicised removal of two NSAIDs,
rofecoxib (2004) and lumaracoxib (2007), from the
Australian market due to cardiovascular and hepatic tox-
icity, respectively [47,48].
However, the reduced likelihood of continuing NSAIDs
compared to acetaminophen predicted from this study
seems to be at odds with the high levels of self-reported
use of NSAIDs in Australia by people with OA [3]. In light
of the efficacy and improved safety of acetaminophen
in OA compared to NSAIDs [3,5], our findings therefore
reinforce the message that the uptake of guidelines-
recommended acetaminophen in practice would benefit
from ensuring that patient medication decision-making is
supported through the provision of explicit risk/benefit
information.
Medication adherence within a clinical trial is typically
higher than in observational settings [49]. For the LEGS
study, as the treatment was provided free of charge, the
level of medication adherence observed in the trial was
predicted to be higher than would exist outside of the
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the cost-sensitivity analysis: when provided free of
charge as per study protocol, the predicted continuation
of GS is around 91%; however at the average current
monthly price for GS ($20), this figure dropped to below
80%. Such rates of long-term adherence and their sensi-
tivity to out-of-pocket costs will need to be factored into
translation of the findings into policy and future eco-
nomic evaluations.
The findings of this study must be viewed in light of
its limitations. First, this study was conducted within a
clinical-trial population, which may affect the generalis-
ability of results. In particular, the self-reported adher-
ence to medications and the proportion of participants
using “when required” medications in this study was
high. However, current medication use and self-reported
adherence did not improve the model fit, suggesting that
such preferences are formed independent of self-reported
medication-taking behaviour.
Second, while discrete choice methods are widely used
in health economics, an inherent limitation is that re-
spondents are evaluating hypothetical medications; what
respondents declare they will do may be quite different
to what they would actually do if faced with the conse-
quences of a choice. Forcing respondents to choose be-
tween medications may also be contrary to actual
behaviour, particularly considering the over-riding influ-
ence of a prescriber’s recommendations upon patient
preventive treatment decisions [22,50]. To minimise
such potential differences, measures were taken to de-
sign the hypothetical tasks to be realistic, for instance by
centring levels of cost on current treatment costs and
describing pain on the same scale used throughout the
clinical trial. Encouragingly, in this study, trust in pre-
scribers and the actual self-reported adherence did not
influence the model results. Nonetheless, to investigate
the relationship between relative preferences captured in
this study and one’s absolute preference to adhere to
medications, future research incorporating the influence
of the prescribers recommendation, for instance by
allowing respondents to opt out of the non-adherent
choice [31,50], is warranted.
Finally, as the constant term (α) was significant, the
factors included in this study do not explain all of the
behaviour modelled. Further work is therefore needed to
clarify which other factors are being considered in ad-
herence decisions.
Conclusions
Osteoarthritis is a chronic condition incurring considerable
costs to most health care systems. As with any chronic con-
dition, non-adherence to the available pharmacological
treatments is a problem that has the potential to impact on
population health and expenditure. In the context of aclinical trial assessing therapy effectiveness, non-adherence
has the potential to derail translation into clinical practice.
By recognising that a component of this health behaviour
is intentional and subject to rational choices, this study
has characterised the complexity of medication-taking deci-
sions for people with symptomatic OA that may lead to
intentionally non-adherent behaviour, identifying the treat-
ment factors driving such decisions. Such factors may be
amenable to intervention such as strategic pricing. The sali-
ence of medication risks in such choices highlights the im-
portance of providing appropriate risk/benefit information
upon prescription. Cost was also a strong consideration in
medication-taking decisions, a finding that ought to be ac-
knowledged when interpreting clinical trial evidence for
practice. Ultimately addressing these factors may be the
way forward to realising the full potential health and eco-
nomic benefits from the efficacious and safe use of osteo-
arthritis medications.Additional files
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